ABVC BioPharma Receives $450,000 in Q3 Licensing Payments from OncoX Partnership

ABVC BioPharma has received $450,000 in licensing payments from partner OncoX BioPharma during the third quarter of 2025, including $350,000 received in August. These payments represent continued execution of a strategic alliance focused on developing innovative oncology therapies and demonstrate the growing commercial potential of ABVC's pipeline.

The licensing agreement entitles ABVC to 5,000,000 OncoX shares and $2,500,000 in cash payments plus future royalties. To date, ABVC has received $650,000 in cash payments, with $1,850,000 remaining receivable and the 5,000,000 OncoX shares already secured. The collaboration holds significant importance as it addresses four major oncology indications that have received FDA Investigational New Drug approvals: Triple Negative Breast Cancer, Non-Small Cell Lung Cancer, Myelodysplastic Syndromes, and Pancreatic Cancer.

The partnership's value extends beyond immediate cash flows, with the consolidated framework exceeding $41 million excluding future royalty streams. This development matters because it positions ABVC to capitalize on the rapidly expanding global cancer therapeutics market, which was valued at approximately US$194.67 billion in 2024 and is projected to reach US$469.38 billion by 2034, growing at a compound annual growth rate of 9.2%.

Dr. Uttam Patil, ABVC's Chief Executive Officer, emphasized that at the group level including subsidiary BioLite, ABVC collectively is entitled to $3.75 million in total cash consideration and 7.5 million OncoX shares. This broader perspective highlights both immediate liquidity and long-term equity value embedded in the partnership. The OncoX collaboration represents a strategic approach to oncology drug development that combines innovation with financial stability through structured licensing agreements.

The market opportunity is substantial, with another industry report available at Synapse Patsnap indicating the global cancer therapeutics market was valued at approximately US$164 billion in 2022 and projected to reach US$393 billion by 2032. These growth projections underscore the importance of strategic partnerships in bringing novel cancer treatments to market while managing development costs and financial risk.

For patients and healthcare providers, this partnership advancement signals progress in developing new treatment options for difficult-to-treat cancers using botanical-derived approaches. The financial stability provided by these licensing payments enables continued research and development efforts that could ultimately lead to new therapeutic options addressing unmet medical needs in oncology.